The Angiogenesis Foundation
| Company type | Non-profit |
|---|---|
| Founded | 1994 in Cambridge, MA |
| Founder | William W. Li, MD and Vincent W. Li, MD (co-founders) |
| Headquarters | Cambridge, MA, U.S. |
| Revenue | 1,772,286 United States dollar (2017)  |
| Total assets | 359,298 United States dollar (2022) |
| Website | angio.org |
The Angiogenesis Foundation, is a United States 501(c)(3) nonprofit organization established in 1994 for the study of angiogenesis. The foundation developed a therapy for canine cancer, called the Navy Protocol. This treatment works by starving the tumor of its blood supply.[1] In 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer.[2] In 2010, the president and co-founder of the Angiogenesis Foundation, William Li, gave a well-received presentation at the TED conference on cancer prevention through antiangiogenic nutrition.[3]
Co-founder Dr. William Li won the 2024 Dr. Andrew von Eschenbach Award for his work in angiogenesis.[4]
References
- ↑ Dog's tale of survival opens door in cancer research, July 24, 2002
- ↑ Colon cancer drug seen as long awaited victory, February 26, 2004
- ↑ Li, William (2010-05-17). William Li: Können wir essen, um Krebs auszuhungern?. Retrieved 2025-02-14 – via www.ted.com.
- ↑ The Angiogenesis Foundation Chief Executive Officer Dr. William Li Was Honored As the Inaugural Recipient of the Dr. Andrew Von Eschenbach Award
External links
- Official website
- "The Angiogenesis Foundation Receives Highest Rating from Charity Navigator" - The Providence Journal, Nov. 7, 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.